Related Experiment Video
Updated: Jun 25, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Evaluating co-primary endpoints collectively in clinical trials.
1Center for Drug Evaluation and Research, US FDA, Silve Spring, MD 20993, USA. qian.li@fda.hhs.gov
Biometrical Journal. Biometrische Zeitschrift
|February 17, 2009
Summary
New statistical methods allow flexible evaluation of co-primary endpoints in clinical trials. This approach controls the risk of approving ineffective treatments while allowing minor variations in statistical significance for co-primary endpoints.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Pharmaceutical Research
Background:
- Co-primary endpoints are frequently used in clinical trials to provide a comprehensive assessment of treatment efficacy.
- Evaluating multiple endpoints collectively is crucial for strengthening evidence of treatment effect.
Purpose of the Study:
- To develop statistical methods for collectively evaluating co-primary endpoints in clinical trials.
- To establish decision rules that control the error rate of wrongly approving ineffective treatments.
Main Methods:
- Development of novel statistical decision rules for the collective evaluation of co-primary endpoints.
- Methods designed to control the overall Type I error rate at 0.025 for studies.
- Rules also account for scenarios where a treatment may be effective for all but one co-primary endpoint.
Main Results:
- The proposed decision rules effectively control the error rate of wrongly accepting an ineffective treatment.
- The methods allow for controlled variation in p-values around the 0.025 significance level for co-primary endpoints.
- Error rates for individual endpoints are also managed within the decision framework.
Conclusions:
- Flexible statistical methods can be applied to co-primary endpoint evaluation in clinical trials.
- These methods offer a more nuanced approach to controlling statistical errors compared to requiring all endpoints to meet strict significance levels.
- The developed decision rules have practical applications in optimizing clinical trial design and analysis.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...